Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research.
Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research.
复制标题
脑源性神经营养因子和神经生长因子治疗脑损伤：当前临床前和临床研究的转化挑战。
DOI：
10.1155/2022/3889300
复制
发表时间：
2022
影响因子：
3.1
通讯作者：
Sims-Robinson C
中科院分区：
文献类型：
--
作者：
Sims SK;Wilken-Resman B;Smith CJ;Mitchell A;McGonegal L;Sims-Robinson C
缺血性中风和创伤性脑损伤(TBI)是世界范围内导致死亡和残疾的主要原因之一，其损害从轻微到严重不等。许多疗法旨在通过靶向神经修复来改善功能和认知恢复，但遇到了涉及疗效和药物输送的问题。因此，患者的治疗选择很少。神经营养因子是神经可塑性和功能恢复的关键介质之一。神经营养因子，如脑源性神经营养因子(BDNF)和神经生长因子(NGF)，在促进神经保护和再生的同时，成为促进神经修复和恢复的潜在治疗选择。BDNF和NGF已经在临床前研究中证明了改善功能恢复的能力，在较小程度的临床研究中也证明了这一点。在动物模型中增加神经营养因子水平的直接和间接方法在改善损伤后结果方面取得了成功。然而，将这些研究转化为临床试验的工作一直受到限制。临床前试验在很大程度上未能在临床研究中产生重大影响。这篇综述将集中于这些神经营养因子在临床前和临床卒中和脑外伤中的应用，以及将这些疗法从试验台转化到临床所面临的挑战。
Ischemic stroke and traumatic brain injury (TBI) are among the leading causes of death and disability worldwide with impairments ranging from mild to severe. Many therapies are aimed at improving functional and cognitive recovery by targeting neural repair but have encountered issues involving efficacy and drug delivery. As a result, therapeutic options for patients are sparse. Neurotrophic factors are one of the key mediators of neural plasticity and functional recovery. Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) serve as potential therapeutic options to increase neural repair and recovery as they promote neuroprotection and regeneration. BDNF and NGF have demonstrated the ability to improve functional recovery in preclinical and to a lesser extent clinical studies. Direct and indirect methods to increase levels of neurotrophic factors in animal models have been successful in improving postinjury outcome measures. However, the translation of these studies into clinical trials has been limited. Preclinical experiments have largely failed to result in significant impacts in clinical research. This review will focus on the administration of these neurotrophic factors in preclinical and clinical stroke and TBI and the challenges in translating these therapies from the bench to the clinic.
登录
查看更多内容
DOI：
10.1007/s00406-007-0764-9
发表时间：
2008-03-01
影响因子：
4.7
作者：
Leyhe, T.;Stransky, E.;Laske, C.
通讯作者：
Laske, C.
DOI：
10.1016/j.annonc.2020.05.006
发表时间：
2020-09
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Liu D;Flory J;Lin A;Offin M;Falcon CJ;Murciano-Goroff YR;Rosen E;Guo R;Basu E;Li BT;Harding JJ;Iyer G;Jhaveri K;Gounder MM;Shukla NN;Roberts SS;Glade-Bender J;Kaplanis L;Schram A;Hyman DM;Drilon A
通讯作者：
Drilon A
DOI：
10.1073/pnas.93.8.3679
发表时间：
1996-04-16
影响因子：
11.1
作者：
Jovanovic, JN;Benfenati, F;Czernik, AJ
通讯作者：
Czernik, AJ
影响因子：
5.3
作者：
Rocco ML;Soligo M;Manni L;Aloe L
通讯作者：
Aloe L
影响因子：
3.7
作者：
Kim JM;Stewart R;Park MS;Kang HJ;Kim SW;Shin IS;Kim HR;Shin MG;Cho KH;Yoon JS
通讯作者：
Yoon JS